VolitionRX Ltd (VNRX) Stock Analysis

What VolitionRX Ltd does

VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.

Key metrics

ETFs linked to VNRX

Broad-market and Healthcare sector ETFs an investor holding VolitionRX Ltd is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how VNRX fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for VolitionRX Ltd?

VolitionRX Ltd trades under the ticker VNRX on AMEX.

Which exchange is VNRX listed on?

VNRX is listed on AMEX.

What sector does VolitionRX Ltd operate in?

VolitionRX Ltd is classified in the Healthcare sector (Medical - Devices industry).

How can PortView help analyze VNRX in a portfolio?

PortView shows VNRX's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.